. | n* . | Sensitivity . | Specificity . | PPV . | NPV . | % correct . | κ . |
---|---|---|---|---|---|---|---|
Definite clinical neuropathy | |||||||
Total cohort | 1,170 | 80 (76–84) | 51 (47–54) | 49 | 81 | 62 | 0.271 |
Aged 36–50 years | 691 | 75 (69–81) | 50 (46–55) | 42 | 81 | 58 | 0.208 |
Aged 51–65 years | 420 | 87 (82–92) | 47 (41–54) | 59 | 80 | 66 | 0.330 |
Abnormal nerve conduction | |||||||
Total cohort | 1,170 | 75 (72–78) | 62 (58–67) | 76 | 61 | 70 | 0.271 |
Aged 36–50 years | 691 | 72 (68–77) | 63 (57–68) | 74 | 61 | 68 | 0.350 |
Aged 51–65 years | 420 | 81 (76–85) | 57 (48–65) | 80 | 58 | 73 | 0.377 |
Confirmed clinical neuropathy | |||||||
Total cohort | 1,170 | 87 (84–91) | 51 (47–54) | 43 | 90 | 62 | 0.296 |
Aged 36–50 years | 691 | 84 (78–89) | 51 (46–55) | 37 | 90 | 59 | 0.241 |
Aged 51–65 years | 420 | 93 (89–97) | 47 (41–53) | 53 | 91 | 65 | 0.348 |
. | n* . | Sensitivity . | Specificity . | PPV . | NPV . | % correct . | κ . |
---|---|---|---|---|---|---|---|
Definite clinical neuropathy | |||||||
Total cohort | 1,170 | 80 (76–84) | 51 (47–54) | 49 | 81 | 62 | 0.271 |
Aged 36–50 years | 691 | 75 (69–81) | 50 (46–55) | 42 | 81 | 58 | 0.208 |
Aged 51–65 years | 420 | 87 (82–92) | 47 (41–54) | 59 | 80 | 66 | 0.330 |
Abnormal nerve conduction | |||||||
Total cohort | 1,170 | 75 (72–78) | 62 (58–67) | 76 | 61 | 70 | 0.271 |
Aged 36–50 years | 691 | 72 (68–77) | 63 (57–68) | 74 | 61 | 68 | 0.350 |
Aged 51–65 years | 420 | 81 (76–85) | 57 (48–65) | 80 | 58 | 73 | 0.377 |
Confirmed clinical neuropathy | |||||||
Total cohort | 1,170 | 87 (84–91) | 51 (47–54) | 43 | 90 | 62 | 0.296 |
Aged 36–50 years | 691 | 84 (78–89) | 51 (46–55) | 37 | 90 | 59 | 0.241 |
Aged 51–65 years | 420 | 93 (89–97) | 47 (41–53) | 53 | 91 | 65 | 0.348 |
Data are % (95% CI) unless otherwise indicated.
*n = 7 subjects who are missing a great toe measurement.